Novel perspectives for hepatitis A virus therapy revealed by comparative analysis of hepatitis C virus and hepatitis A virus RNA replication

Hepatology

Volumn 62, Issue 2, 2015, Pages 397-408

  Esser Nobis, Katharina ^a   Harak, Christian ^a   Schult, Philipp ^a   Kusov, Yuri ^b   Lohmann, Volker ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; CYCLOSPORIN A; GENOMIC RNA; IMMUNOPHILIN; INTERFERON; MICRORNA 122; MULTIDRUG RESISTANCE PROTEIN; PHOSPHATIDYLINOSITOL 4 KINASE III ALPHA; PHOSPHATIDYLINOSITOL 4 KINASE III BETA; PHOSPHATIDYLINOSITOL KINASE; SHORT HAIRPIN RNA; SILIBININ; UNCLASSIFIED DRUG; VIRUS RNA;

ARTICLE; CELL CLONE; COMPARATIVE STUDY; ELECTROPORATION; GENETIC TRANSFECTION; GENOME; GENOTYPE; HEPATITIS A VIRUS; HEPATITIS C VIRUS; HOST CELL; HOST RESISTANCE; HUMAN; HUMAN CELL; IC50; INNATE IMMUNITY; LIVER PROTECTION; NONHUMAN; PRIORITY JOURNAL; REPLICON; RNA BINDING; RNA REPLICATION; VIRAL CLEARANCE; VIROTHERAPY; VIRUS REPLICATION; CELL CULTURE; DRUG EFFECTS; FEMALE; GENETICS; HEPACIVIRUS; HEPATITIS A; HEPATITIS B; MALE; PHYSIOLOGY; SENSITIVITY AND SPECIFICITY;

CELLS, CULTURED; FEMALE; HEPACIVIRUS; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS B; HUMANS; INTERFERONS; MALE; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIRUS REPLICATION;

EID: 84938208358     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27847     Document Type: Article

References (38)

1. Thimme R, Binder M, Bartenschlager R. Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. FEMS Microbiol Rev 2012;36:663-683.
2. Lanford RE, Feng Z, Chavez D, Guerra B, Brasky KM, Zhou Y, et al. Acute hepatitis A virus infection is associated with a limited type I interferon response and persistence of intrahepatic viral RNA. Proc Natl Acad Sci U S A 2011;108:11223-11228.
3. FitzSimons D, Hendrickx G, Vorsters A, Van Damm P. Hepatitis A and E: update on prevention and epidemiology. Vaccine 2010;28:583-588.
4. Fitzgerald M, Thornton L, O'Gorman J, O'Connor L, Garvey P, Boland M, et al. Outbreak of hepatitis A infection associated with the consumption of frozen berries, Ireland, 2013-linked to an international outbreak. Euro Surveill 2014;19(43). pii: 20942.
5. Collier MG, Khudyakov YE, Selvage D, Adams-Cameron M, Epson E, Cronquist A, et al. Outbreak of hepatitis A in the USA associated with frozen pomegranate arils imported from Turkey: an epidemiological case study. Lancet Infect Dis 2014;14:976-981.
6. Vento S. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. J Viral Hepat 2000;7(Suppl 1):7-8.
7. Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol 2013;11:482-496.
8. Hsu NY, Ilnytska O, Belov G, Santiana M, Chen YH, Takvorian PM, et al. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell 2010;141:799-811.
9. Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, et al. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 2011;9:32-45.
10. Bianco A, Reghellin V, Donnici L, Fenu S, Alvarez R, Baruffa C, et al. Metabolism of phosphatidylinositol 4-kinase IIIalpha-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity. PLoS Pathog 2012;8:e1002576.
11. Borawski J, Troke P, Puyang X, Gibaja V, Zhao S, Mickanin C, et al. Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication. J Virol 2009;83:10058-10074.
12. Gaither LA, Borawski J, Anderson LJ, Balabanis KA, Devay P, Joberty G, et al. Multiple cyclophilins involved in different cellular pathways mediate HCV replication. Virology 2010;397:43-55.
13. Burkhart CA, Watt F, Murray J, Pajic M, Prokvolit A, Xue C, et al. Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. Cancer Res 2009;69:6573-6580.
14. Bhardwaj RK, Glaeser H, Becquemont L, Klotz U, Gupta SK, Fromm MF. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002;302:645-650.
15. Binder M, Quinkert D, Bochkarova O, Klein R, Kezmic N, Bartenschlager R, et al. Identification of determinants involved in initiation of hepatitis C virus RNA synthesis by using intergenotypic replicase chimeras. J Virol 2007;81:5270-5283.
16. Kaul A, Stauffer S, Berger C, Pertel T, Schmitt J, Kallis S, et al. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog 2009;5:e1000546.
17. Gauss-Muller V, Kusov YY. Replication of a hepatitis A virus replicon detected by genetic recombination in vivo. J Gen Virol 2002;83(Pt 9):2183-2192.
18. Esser-Nobis K, Romero-Brey I, Ganten TM, Gouttenoire J, Harak C, Klein R, et al. Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B. Hepatology 2013;57:953-963.
19. Schmitt M, Scrima N, Radujkovic D, Caillet-Saguy C, Simister PC, Friebe P, et al. A comprehensive structure-function comparison of hepatitis C virus strain JFH1 and J6 polymerases reveals a key residue stimulating replication in cell culture across genotypes. J Virol 2011;85:2565-2581.
20. Lohmann V. Hepatitis C virus RNA replication. Curr Top Microbiol Immunol 2013;369:167-198.
21. Frausto SD, Lee E, Tang H. Cyclophilins as modulators of viral replication. Viruses 2013;5:1684-1701.
22. Gallay PA. Cyclophilin inhibitors. Clin Liver Dis 2009;13:403-417.
23. Watanabe T, Kokubu N, Charnick SB, Naito M, Tsuruo T, Cohen D. Interaction of cyclosporin derivatives with the ATPase activity of human P-glycoprotein. Br J Pharmacol 1997;122:241-248.
24. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008;9:105-127.
25. Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice. World J Gastroenterol 2011;17:2288-2301.
26. Martin A, Lemon SM. Hepatitis A virus: from discovery to vaccines. Hepatology 2006;43(2 Suppl 1):S164-S172.
27. Wieland S, Makowska Z, Campana B, Calabrese D, Dill MT, Chung J, et al. Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. Hepatology 2014;59:2121-2130.
28. Sheahan T, Imanaka N, Marukian S, Dorner M, Liu P, Ploss A, et al. Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe 2014;15:190-202.
29. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science 2005;309:623-626.
30. Debing Y, Kaplan GG, Neyts J, Jochmans D. Rapid and convenient assays to assess potential inhibitory activity on in vitro hepatitis A replication. Antiviral Res 2013;98:325-331.
31. Delang L, Paeshuyse J, Neyts J. The role of phosphatidylinositol 4-kinases and phosphatidylinositol 4-phosphate during viral replication. Biochem Pharmacol 2012;84:1400-1408.
32. Wang X, Ren J, Gao Q, Hu Z, Sun Y, Li X, et al. Hepatitis A virus and the origins of picornaviruses. Nature 2015;517:85-88.
33. Carbajo-Lozoya J, Muller MA, Kallies S, Thiel V, Drosten C, von Brunn A. Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506. Virus Res 2012;165:112-117.
34. Fu J, Tjandra M, Becker C, Bednarczyk D, Capparelli M, Elling R, et al. Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition. J Med Chem 2014;57:8503-8516.
35. Sweeney ZK, Fu J, Wiedmann B. From chemical tools to clinical medicines: nonimmunosuppressive cyclophilin inhibitors derived from the cyclosporin and sanglifehrin scaffolds. J Med Chem 2014;57:7145-7159.
36. Gallay PA, Lin K. Profile of alisporivir and its potential in the treatment of hepatitis C. Drug Des Devel Ther 2013;7:105-115.
37. Polyak SJ, Oberlies NH, Pecheur EI, Dahari H, Ferenci P, Pawlotsky JM. Silymarin for HCV infection. Antivir Ther 2013;18:141-147.
38. Fried MW, Navarro VJ, Afdhal N, Belle SH, Wahed AS, Hawke RL, et al. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA 2012;308:274-282.